# Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

> **NCT02850406** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 147 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Voxelotor

## Key facts

- **NCT ID:** NCT02850406
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-05
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-10-02
- **Target enrollment:** 147 (ACTUAL)
- **Why stopped:** Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02850406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02850406, "Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02850406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*